192 related articles for article (PubMed ID: 30380358)
21. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
22. Use of Bayesian Markov chain Monte Carlo methods to estimate EQ-5D utility scores from EORTC QLQ data in myeloma for use in cost-effectiveness analysis.
Kharroubi SA; Edlin R; Meads D; Browne C; Brown J; McCabe C
Med Decis Making; 2015 Apr; 35(3):351-60. PubMed ID: 25784746
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
24. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
[TBL] [Abstract][Full Text] [Related]
25. Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry.
van der Poel MW; Oerlemans S; Schouten HC; van de Poll-Franse LV
Ann Hematol; 2015 Apr; 94(4):651-61. PubMed ID: 25471174
[TBL] [Abstract][Full Text] [Related]
26. Reliability and Validity of an Iranian Version of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Multiple Myeloma: the EORTC QLQ-MY20.
Ahmadzadeh A; Yekaninejad MS; Saffari M; Pakpour AH; Aaronson NK
Asian Pac J Cancer Prev; 2016; 17(1):255-9. PubMed ID: 26838220
[TBL] [Abstract][Full Text] [Related]
27. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.
Ramsenthaler C; Osborne TR; Gao W; Siegert RJ; Edmonds PM; Schey SA; Higginson IJ
BMC Cancer; 2016 Jul; 16():427. PubMed ID: 27387201
[TBL] [Abstract][Full Text] [Related]
28. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life.
Stead ML; Brown JM; Velikova G; Kaasa S; Wisløff F; Child JA; Hippe E; Hjorth M; Sezer O; Selby P
Br J Haematol; 1999 Mar; 104(3):605-11. PubMed ID: 10086801
[TBL] [Abstract][Full Text] [Related]
29. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
30. Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France.
Despiégel N; Touboul C; Flinois A; Saba G; Suzan F; Gonzalez-McQuire S; Bonnetain F
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e13-e28. PubMed ID: 30292736
[TBL] [Abstract][Full Text] [Related]
31. Validation of the Quality of Life Multiple Myeloma Module Questionnaire (QLQ-MY20) in Portuguese myeloma patients.
Graça Pereira M; Ferreira G; Pereira M; Faria S; Bacalhau R; Monteiro S; Fernandes B; Vilaça M
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13128. PubMed ID: 31273859
[TBL] [Abstract][Full Text] [Related]
32. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
Rowen D; Young T; Brazier J; Gaugris S
Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
[TBL] [Abstract][Full Text] [Related]
33. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
34. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
35. Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma.
Chakraborty R; Hamilton BK; Hashmi SK; Kumar SK; Majhail NS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1546-1553. PubMed ID: 29626515
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma.
de Lima MSR; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM
Support Care Cancer; 2023 Jun; 31(7):379. PubMed ID: 37278732
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
Ludwig H; Moreau P; Dimopoulos MA; Mateos MV; Kaiser M; Hajek R; Feng S; Cocks K; Buchanan J; Weisel K
Blood Cancer J; 2019 Feb; 9(3):23. PubMed ID: 30796199
[TBL] [Abstract][Full Text] [Related]
38. Individual quality of life of patients undergoing autologous peripheral blood stem cell transplantation.
Frick E; Borasio GD; Zehentner H; Fischer N; Bumeder I
Psychooncology; 2004 Feb; 13(2):116-24. PubMed ID: 14872530
[TBL] [Abstract][Full Text] [Related]
39. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
40. Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy.
Jackson G; Galinsky J; Alderson DEC; D'Souza VK; Buchanan V; Dhanasiri S; Walker S
Eur J Haematol; 2019 Oct; 103(4):393-401. PubMed ID: 31325331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
